TCR-T
Showing 1 - 25 of 8,301
EBV Infection After Allogenic HSCT Trial in Beijing (EBV-TCR-T cells)
Recruiting
- EBV Infection After Allogenic HSCT
- EBV-TCR-T cells
-
Beijing, Beijing, ChinaChinese PLA General Hospital
Nov 3, 2023
EBV-associated Hemophagocytic Lymphohistiocytosis, EBV Infection Trial in Beijing (EBV-TCR-T cells)
Recruiting
- EBV-associated Hemophagocytic Lymphohistiocytosis
- EBV Infection
- EBV-TCR-T cells
-
Beijing, Beijing, ChinaChinese PLA General Hospital
Nov 12, 2023
Pancreatic Cancer Trial in ShangHai (TCR-T Cells Injection(GB3010 Cells Injection))
Recruiting
- Pancreatic Cancer
- TCR-T Cells Injection（GB3010 Cells Injection）
-
ShangHai, Shanghai, ChinaRuijin Hospital Affiliated to Shanghai Jiaotong University Schoo
Sep 19, 2023
Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Oropharyngeal Cancer Trial in Shanghai (Fludarabine + Cyclophosphamide,
Not yet recruiting
- Cervical Cancer
- +6 more
- Fludarabine + Cyclophosphamide
- HRYZ-T101 TCR-T Cell
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Mar 27, 2023
HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Malignancy Trial in New Brunswick (Conditioning, E7 TCR-T
Not yet recruiting
- HPV-Associated Cervical Carcinoma
- +16 more
- Conditioning, E7 TCR-T cells, and aldesleukin
-
New Brunswick, New JerseyRutgers Cancer Institute of New Jersey
Jan 17, 2023
Chronic Hepatitis B Trial in Beijing (TCR-T)
Active, not recruiting
- Chronic Hepatitis B
- TCR-T
-
Beijing, ChinaThe Fifth Medical Center of PLA General Hospital
Jun 13, 2023
Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 Trial in Seattle (Autologous Mesothelin-specific
Recruiting
- Metastatic Pancreatic Ductal Adenocarcinoma
- Stage IV Pancreatic Cancer AJCC v8
- Autologous Mesothelin-specific TCR-T Cells
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 31, 2023
Advanced Soft-tissue Sarcoma Trial in Shenzhen (NY-ESO-1 TCR-T)
Recruiting
- Advanced Soft-tissue Sarcoma
- NY-ESO-1 TCR-T
-
Shenzhen, Guangdong, ChinaLi Yu
Nov 17, 2022
Nasopharyngeal Carcinoma Trial (PK Blood Collection, CAR, TCR)
Not yet recruiting
- Nasopharyngeal Carcinoma
- PK Blood Collection
- +2 more
- (no location specified)
Nov 1, 2022
Preclinical Research for Personalized TCR-T Therapy for Head and
Recruiting
- Head and Neck Cancer
- No intervention
-
Shanghai, Shanghai, ChinaEye & ENT Hospital of Fudan University
Jan 15, 2023
Solid Tumors Trial (TCR-T cells, Fludarabine, Cyclophosphamide Capsules)
Not yet recruiting
- Solid Tumors
- TCR-T cells
- +4 more
- (no location specified)
Dec 12, 2022
Pancreatic Cancer Trial in Guangzhou (TCR-T therapy)
Recruiting
- Pancreatic Cancer
- TCR-T therapy
-
Guangzhou, Guangdong, ChinaSun Yat-sen Memorial Hospital
Aug 10, 2022
TCR-T Cells, Refractory Solid Tumors, Relapsed Solid Tumors Trial in Nanning (KSH01 injection)
Recruiting
- TCR-T Cells
- +2 more
- KSH01 injection
-
Nanning, Guang XI, ChinaThe first affiliated hospital of Guang Xi medical university
Sep 14, 2022
Cervical Carcinoma Trial in Chongqing (TC-E202 cells, IL-2, Fludarabine)
Recruiting
- Cervical Carcinoma
- TC-E202 cells
- +3 more
-
Chongqing, Chongqing, ChinaXiaochun Cheng
Oct 20, 2022
Malignant Epithelial Tumors Trial in Portland (TCR-transduced T cells, CDX-1140, Pembrolizumab)
Not yet recruiting
- Malignant Epithelial Neoplasms
- TCR-transduced T cells
- +2 more
-
Portland, OregonProvidence Portland Medical Center
Apr 22, 2022
Cervical Cancer, Anal Cancer, Head Neck Cancers Trial in Zhengzhou (Fludarabine + Cyclophosphamide, Interleukin-2, CRTE7A2-01
Recruiting
- Cervical Cancer
- +2 more
- Fludarabine + Cyclophosphamide
- +2 more
-
Zhengzhou, Henan, ChinaThe First Affiliated Hospital of Zhengzhou University
Jun 22, 2022
Safety and Efficacy of TCR-like CAR-T Trial in Nanjing (TCR-like CAR-T)
Recruiting
- Safety and Efficacy of TCR-like CAR-T
- TCR-like CAR-T
-
Nanjing, Jiangsu, ChinaZhongda hospital
Jul 26, 2023
Hepatocellular Carcinoma Trial in Guangzhou (TCR-T, No intervention and TCR-T (at crossover))
Completed
- Hepatocellular Carcinoma
- TCR-T
- No intervention and TCR-T (at crossover)
-
Guangzhou, Guangdong, ChinaThe First Affiliated Hospital, Sun-Yat Sen University
Jun 27, 2022
EBV Emia and EBV Positive PTLD After Allogenic HSCT Trial in Sanhe (EBV-TCR-T cells)
Completed
- EBV Emia and EBV Positive PTLD After Allogenic HSCT
- EBV-TCR-T cells
-
Sanhe, Hebei, ChinaHebei Yanda Ludaopei Hospital
Mar 6, 2022
Metastatic Colorectal Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma Trial in
Not yet recruiting
- Metastatic Colorectal Adenocarcinoma
- +5 more
- Bendamustine
- +11 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Sep 12, 2023
Melanoma, Melanoma, Uveal, Head Neck Cancer Trial in Rotterdam (Adoptive therapy with autologous MC2 TCR T cells)
Recruiting
- Melanoma
- +2 more
- Adoptive therapy with autologous MC2 TCR T cells
-
Rotterdam, NetherlandsErasmus Medical Center
Jun 1, 2022
TCR-T Cells, Refractory Solid Tumors, Relapsed Solid Tumors Trial in Nanning (KSX01-TCRT injection)
Recruiting
- TCR-T Cells
- +2 more
- KSX01-TCRT injection
-
Nanning, Guangxi Zhuang Autonomous Region, ChinaThe first affiliated hospital of Guang Xi medical university
Mar 31, 2023
Gastric Cancer, Breast Cancer, Cervical Cancer Trial in New Brunswick (KK-LC-1 TCR-T cells, Aldesleukin 720,000 IU/kg IV every
Not yet recruiting
- Gastric Cancer
- +3 more
- KK-LC-1 TCR-T cells
- Aldesleukin 720,000 IU/kg IV every eight hours
-
New Brunswick, New JerseyRutgers Cancer Institute of New Jersey
Jul 30, 2022
CMV Infection or Reactivation After Allogenic HSCT Trial in Sanhe (CMV-TCR-T cells)
Recruiting
- CMV Infection or Reactivation After Allogenic HSCT
- CMV-TCR-T cells
-
Sanhe, Hebei, ChinaHebei Yanda Ludaopei Hospital
Jan 29, 2022
HLA Typing and Tumor Neoantigen Identification forPhase I/II
Recruiting
- Ovarian Cancer
- +5 more
-
Houston, TexasMD Anderson Cancer Center
Jul 27, 2022